Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Metastatic Pancreatic Adenocarcinoma × Tetrahydrouridine × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1 Neoplasms 1 Metastatic Pancreatic Adenocarcinoma 1 Lymphoma, T-Cell 1 Lung Neoplasms 1 Head and Neck Neoplasms 1 Breast Neoplasms 1

Interventions

Tetrahydrouridine 1 Decitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02847000 2019-01-09

p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Pancreatic Cancer

Case Comprehensive Cancer Center

Phase EARLY_PHASE1 Completed

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡